MINT-ACYCLOVIR TABLET
Страна: Канада
Език: английски
Източник: Health Canada
Данни за продукта
(SPC)
21-01-2022
Понастоящем някои документи за този продукт не са налични, можете да изпратите заявка до нашата служба за клиенти и ние ще ви уведомим веднага щом успеем да ги получим.
Изпрати заяв.
Изпрати заяв.
Активна съставка:
ACYCLOVIR
Предлага се от:
MINT PHARMACEUTICALS INC
АТС код:
J05AB01
INN (Международно Name):
ACYCLOVIR
дозиране:
200MG
Лекарствена форма:
TABLET
Композиция:
ACYCLOVIR 200MG
Начин на приложение:
ORAL
Броя в опаковка:
15G/50G
Вид предписание :
Prescription
Каталог на резюме:
Active ingredient group (AIG) number: 0115506002; AHFS:
Статус Оторизация:
APPROVED
Дата Оторизация:
2022-01-25
Данни за продукта
PRODUCT MONOGRAPH
PR
MINT-ACYCLOVIR
ACYCLOVIR TABLETS USP
200 MG, 400 MG AND 800 MG
ANTIVIRAL AGENT
MINT PHARMACEUTICALS INC.
DATE OF PREPARATION:
6575 DAVAND DRIVE
JANUARY 21, 2022
MISSISSAUGA, ONTARIO
L5T 2M3
Control No. 239932
_MINT-ACYCLOVIR Product Monograph_
_ _
_Page 2 of 37 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................. 3 SUMMARY PRODUCT
INFORMATION........................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
.................................................................................................
4
WARNINGS AND
PRECAUTIONS.................................................................................
4
ADVERSE REACTIONS
.................................................................................................
6
DRUG INTERACTIONS
..................................................................................................
9
DOSAGE AND ADMINISTRATION
...............................................................................
9
OVERDOSAGE
..............................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
.............................................................12
STORAGE AND STABILITY
.........................................................................................14
DOSAGE FORMS, COMPOSITION AND PACKAGING
...............................................14
PART II: SCIENTIFIC
INFORMATION.......................................................................
15
PHARMACEUTICAL INFORMATION
..........................................................................15
CLINICAL TRIALS
........................................................................................................15
DETAILED PHARMACOLOGY
....................................................................................16
VIR
Прочетете целия документ
